Model system to define pharmacokinetic requirements for antimalarial drug efficacy

Science Translational Medicine

Volumn 5, Issue 205, 2013, Pages

  Bakshi, Rahul P ^a,b   Nenortas, Elizabeth ^a   Tripathi, Abhai K ^b   Sullivan, David J ^b   Shapiro, Theresa A ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMISININ; ARTESUNATE; ATOVAQUONE; CHLOROQUINE; DOXYCYCLINE; PYRIMETHAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; IN VITRO STUDY; IN VIVO STUDY; MALARIA; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PHARMACODYNAMICS; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; STRAIN DIFFERENCE; VALIDATION PROCESS;

ANIMALS; ANTIMALARIALS; ARTEMISININS; CHLOROQUINE; DISEASE MODELS, ANIMAL; HUMANS; MALARIA, FALCIPARUM; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; PARASITIC SENSITIVITY TESTS; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 84885453391     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3006684     Document Type: Article

References (49)

1. World Health Organization, World Malaria Report 2010 (World Health Organization, Geneva, 2010).
2. C. J. Murray, L. C. Rosenfeld, S. S. Lim, K. G. Andrews, K. J. Foreman, D. Haring, N. Fullman, M. Naghavi, R. Lozano, A. D. Lopez, Global malaria mortality between 1980 and 2010: A systematic analysis. Lancet 379, 413-431 (2012).
3. A. M. Dondorp, F. Nosten, P. Yi, D. Das, A. P. Phyo, J. Tarning, K. M. Lwin, F. Ariey, W. Hanpithakpong, S. J. Lee, P. Ringwald, K. Silamut, M. Imwong, K. Chotivanich, P. Lim, T. Herdman, S. S. An, S. Yeung, P. Singhasivanon, N. P. Day, N. Lindegardh, D. Socheat, N. J. White, Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361, 455-467 (2009).
4. D. E. Goldberg, R. F. Siliciano, W. R. Jacobs Jr., Outwitting evolution: Fighting drug-resistant TB, malaria, and HIV. Cell 148, 1271-1283 (2012).
5. M. J. Gardner, N. Hall, E. Fung, O. White, M. Berriman, R. W. Hyman, J. M. Carlton, A. Pain, K. E. Nelson, S. Bowman, I. T. Paulsen, K. James, J. A. Eisen, K. Rutherford, S. L. Salzberg, A. Craig, S. Kyes, M. S. Chan, V. Nene, S. J. Shallom, B. Suh, J. Peterson, S. Angiuoli, M. Pertea, J. Allen, J. Selengut, D. Haft, M. W. Mather, A. B. Vaidya, D. M. Martin, A. H. Fairlamb, M. J. Fraunholz, D. S. Roos, S. A. Ralph, G. I. McFadden, L. M. Cummings, G. M. Subramanian, C. Mungall, J. C. Venter, D. J. Carucci, S. L. Hoffman, C. Newbold, R. W. Davis, C. M. Fraser, B. Barrell, Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419, 498-511 (2002).
6. F. J. Gamo, L. M. Sanz, J. Vidal, C. de Cozar, E. Alvarez, J. L. Lavandera, D. E. Vanderwall, D. V. Green, V. Kumar, S. Hasan, J. R. Brown, C. E. Peishoff, L. R. Cardon, J. F. Garcia-Bustos, Thousands of chemical starting points for antimalarial lead identification. Nature 465, 305-310 (2010).
7. W. A. Guiguemde, A. A. Shelat, D. Bouck, S. Duffy, G. J. Crowther, P. H. Davis, D. C. Smithson, M. Connelly, J. Clark, F. Zhu, M. B. Jiménez- Díaz, M. S. Martinez, E. B. Wilson, A. K. Tripathi, J. Gut, E. R. Sharlow, I. Bathurst, F. El Mazouni, J. W. Fowble, I. Forquer, P. L. McGinley, S. Castro, I. Angulo-Barturen, S. Ferrer, P. J. Rosenthal, J. L. Derisi, D. J. Sullivan, J. S. Lazo, D. S. Roos, M. K. Riscoe, M. A. Phillips, P. K. Rathod, W. C. Van Voorhis, V. M. Avery, R. K. Guy, Chemical genetics of Plasmodium falciparum. Nature 465, 311-315 (2010).
8. M. Rottmann, C. McNamara, B. K. Yeung, M. C. Lee, B. Zou, B. Russell, P. Seitz, D. M. Plouffe, N. V. Dharia, J. Tan, S. B. Cohen, K. R. Spencer, G. E. González-Páez, S. B. Lakshminarayana, A. Goh, R. Suwanarusk, T. Jegla, E. K. Schmitt, H. P. Beck, R. Brun, F. Nosten, L. Renia, V. Dartois, T. H. Keller, D. A. Fidock, E. A. Winzeler, T. T. Diagana, Spiroindolones, a potent compound class for the treatment of malaria. Science 329, 1175-1180 (2010).
9. S. Nwaka, R. G. Ridley, Virtual drug discovery and development for neglected diseases through public-private partnerships. Nat. Rev. Drug Discov. 2, 919-928 (2003).
10. M. E. Cartwright, S. Cohen, J. C. Fleishaker, S. Madani, J. F. McLeod, B. Musser, S. A. Williams, Proof of concept: A PhRMA position paper with recommendations for best practice. Clin. Pharmacol. Ther. 87, 278-285 (2010).
11. W. A. Craig, Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26, 1-10; quiz 11-12 (1998).
12. A. N. Brown, J. B. Bulitta, J. J. McSharry, Q. Weng, J. R. Adams, R. Kulawy, G. L. Drusano, Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model. Antimicrob. Agents Chemother. 55, 1747-1753 (2011).
13. G. W. Amsden, C. H. Ballow, J. S. Bertino, A. D. M. Kashuba, in Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, G. L. Mandell, J. E. Bennett, R. Dolin, Eds. (Churchill Livingstone, Philadelphia, PA, 2010), vol. 1, pp. 297-308.
14. G. L. Drusano, Antimicrobial pharmacodynamics: Critical interactions of 'bug and drug'. Nat. Rev. Microbiol. 2, 289-300 (2004).
15. J. M. Prins, H. R. Büller, E. J. Kuijper, R. A. Tange, P. Speelman, Once versus thrice daily gentamicin in patients with serious infections. Lancet 341, 335-339 (1993).
16. M. J. Rybak, B. J. Abate, S. L. Kang, M. J. Ruffing, S. A. Lerner, G. L. Drusano, Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob. Agents Chemother. 43, 1549-1555 (1999).
17. S. Kishi, N. Goto, T. Nakamura, T. Ueda, Evaluation of cell-killing effects of 1-β-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system. Cancer Res. 59, 2629-2634 (1999).
18. N. P. Shah, C. Kasap, C. Weier, M. Balbas, J. M. Nicoll, E. Bleickardt, C. Nicaise, C. L. Sawyers, Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 14, 485-493 (2008).
19. I. Angulo-Barturen, M. B. Jiménez-Díaz, T. Mulet, J. Rullas, E. Herreros, S. Ferrer, E. Jiménez, A. Mendoza, J. Regadera, P. J. Rosenthal, I. Bathurst, D. L. Pompliano, F. Gómez de las Heras, D. Gargallo-Viola, A murine model of falciparum-malaria by in vivo selection of competent strains in non-myelodepleted mice engrafted with human erythrocytes. PLoS One 3, e2252 (2008).
20. J. Blaser, B. B. Stone, S. H. Zinner, Two compartment kinetic model with multiple artificial capillary units. J. Antimicrob. Chemother. 15 (Suppl. A), 131-137 (1985).
21. M. R. Moore, F. M. Hamzeh, F. E. Lee, P. S. Lietman, Activity of (S) -1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine against human cytomegalovirus when administered as single-bolus dose and continuous infusion in in vitro cell culture perfusion system. Antimicrob. Agents Chemother. 38, 2404-2408 (1994).
22. W. Trager, J. B. Jensen, Human malaria parasites in continuous culture. Science 193, 673-675 (1976).
23. T. A. Shapiro, D. E. Goldberg, in Goodman and Gilman's The pharmacological Basis of Therapeutics, L. L. Brunton, J. S. Lazo, K. L. Parker, Eds. (McGraw-Hill Companies, New York, 2006), pp. 1021-1047.
24. L. W. Scheibel, A. Adler, Antimalarial activity of selected aromatic chelators. II. Substituted quinolines and quinoline-N-oxides. Mol. Pharmacol. 20, 218-223 (1981).
25. A. A. Divo, T. G. Geary, J. B. Jensen, Oxygen- and time-dependent effects of antibiotics and selected mitochondrial inhibitors on Plasmodium falciparum in culture. Antimicrob. Agents Chemother. 27, 21-27 (1985).
26. B. Fall, S. Diawara, K. Sow, E. Baret, B. Diatta, K. B. Fall, P. S. Mbaye, F. Fall, Y. Diémé, C. Rogier, B. Wade, R. Bercion, B. Pradines, Ex vivo susceptibility of Plasmodium falciparum isolates from Dakar, Senegal, to seven standard anti-malarial drugs. Malar. J. 10, 310 (2011).
27. L. Osorio, C. Murillo, S. Aponte, V. Mayagaya, C. Scheurer, R. Brun, H. Matile, S. Wittlin, In vitro susceptibility of P. falciparum populations from Colombia and Tanzania to a new synthetic peroxide (OZ277). Am. J. Trop. Med. Hyg. 76, 1024-1026 (2007).
28. J. Yuan, K. C. Cheng, R. L. Johnson, R. Huang, S. Pattaradilokrat, A. Liu, R. Guha, D. A. Fidock, J. Inglese, T. E. Wellems, C. P. Austin, X. Z. Su, Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. Science 333, 724-729 (2011).
29. K. Ganesan, N. Ponmee, L. Jiang, J. W. Fowble, J. White, S. Kamchonwongpaisan, Y. Yuthavong, P. Wilairat, P. K. Rathod, A genetically hard-wired metabolic transcriptome in Plasmodium falciparum fails to mount protective responses to lethal antifolates. PLoS Pathog. 4, e1000214 (2008).
30. S. Mok, M. Imwong, M. J. Mackinnon, J. Sim, R. Ramadoss, P. Yi, M. Mayxay, K. Chotivanich, K. Y. Liong, B. Russel, D. Socheat, P. N. Newton, N. P. Day, N. J. White, P. R. Preiser, F. Nosten, A. M. Dondorp, Z. Bozdech, Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription. BMC Genomics 12, 391 (2011).
31. M. Torrentino-Madamet, L. Alméras, J. Desplans, Y. Le Priol, M. Belghazi, M. Pophillat, P. Fourquet, Y. Jammes, D. Parzy, Global response of Plasmodium falciparum to hyperoxia: A combined transcriptomic and proteomic approach. Malar. J. 10, 4 (2011).
32. T. Li, S. Glushakova, J. Zimmerberg, A new method for culturing Plasmodium falciparum shows replication at the highest erythrocyte densities. J. Infect. Dis. 187, 159-162 (2003).
33. P. Preechapornkul, K. Chotivanich, M. Imwong, A. M. Dondorp, S. J. Lee, N. P. Day, N. J. White, S. Pukrittayakamee, Optimizing the culture of Plasmodium falciparum in hollow fiber bioreactors. Southeast Asian J. Trop. Med. Public Health 41, 761-769 (2010).
34. S. Krishna, N. J. White, Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin. Pharmacokinet. 30, 263-299 (1996).
35. Y. Suputtamongkol, P. N. Newton, B. Angus, P. Teja-Isavadharm, D. Keeratithakul, M. Rasameesoraj, S. Pukrittayakamee, N. J. White, A comparison of oral artesunate and artemether antimalarial bioactivities in acute falciparum malaria. Br. J. Clin. Pharmacol. 52, 655-661 (2001).
36. P. N. Newton, K. I. Barnes, P. J. Smith, A. C. Evans, W. Chierakul, R. Ruangveerayuth, N. J. White, The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria. Eur. J. Clin. Pharmacol. 62, 1003-1009 (2006).
37. N. Klonis, S. C. Xie, J. M. McCaw, M. P. Crespo-Ortiz, S. G. Zaloumis, J. A. Simpson, L. Tilley, Altered temporal response of malaria parasites determines differential sensitivity to artemisinin. Proc. Natl. Acad. Sci. U.S.A. 110, 5157-5162 (2013).
38. A. Benakis, M. Paris, L. Loutan, C. T. Plessas, S. T. Plessas, Pharmacokinetics of artemisinin and artesunate after oral administration in healthy volunteers. Am. J. Trop. Med. Hyg. 56, 17-23 (1997).
39. D. Bunnag, C. Viravan, S. Looareesuwan, J. Karbwang, T. Harinasuta, Double blind randomised clinical trial of oral artesunate at once or twice daily dose in falciparum malaria. Southeast Asian J. Trop. Med. Public Health 22, 539-543 (1991).
40. M. H. Alin, A. Bjorkman, Concentration and time dependency of artemisinin efficacy against Plasmodium falciparum in vitro. Am. J. Trop. Med. Hyg. 50, 771-776 (1994).
41. R. D. Young, P. K. Rathod, Clonal viability measurements on Plasmodium falciparum to assess in vitro schizonticidal activity of leupeptin, chloroquine, and 5-fluoroorotate. Antimicrob. Agents Chemother. 37, 1102-1107 (1993).
42. E. Mapaba, U. Hellgren, A. Landberg-Lindgren, L. Rombo, Susceptibility of Plasmodium falciparum to quinine in vitro: Effects of drug concentrations and time of exposure. Trans. R. Soc. Trop. Med. Hyg. 89, 85-89 (1995).
43. F. Mphande, S. Nillson, A. Bolad, in Methods in Malaria Research, K. Moll, I. Ljungstrom, H. Perlmann, A. Scherf, M. Wahlgren, Eds. (Malaria Research and Reference Reagent Resource Center (MR4), Manassas, VA, 2008), pp. 1-3.
44. L. W. Scheibel, S. H. Ashton, W. Trager, Plasmodium falciparum: Microaerophilic requirements in human red blood cells. Exp. Parasitol. 47, 410-418 (1979).
45. A. G. Tsai, P. C. Johnson, M. Intaglietta, Oxygen gradients in the microcirculation. Physiol. Rev. 83, 933-963 (2003).
46. H. Atamna, H. Ginsburg, The malaria parasite supplies glutathione to its host cell - Investigation of glutathione transport and metabolism in human erythrocytes infected with Plasmodium falciparum. Eur. J. Biochem. 250, 670-679 (1997).
47. R. E. Desjardins, C. J. Canfield, J. D. Haynes, J. D. Chulay, Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob. Agents Chemother. 16, 710-718 (1979).
48. G. H. Posner, L. González, J. N. Cumming, D. Klinedinst, T. A. Shapiro, Synthesis and antimalarial activity of heteroatom-containing bicyclic endoperoxides. Tetrahedron 53, 37-50 (1997).
49. T. Gumbo, A. Louie, M. R. Deziel, W. Liu, L. M. Parsons, M. Salfinger, G. L. Drusano, Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob. Agents Chemother. 51, 3781-3788 (2007).